NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy and Safety Results Abstract #1508

Introduction: There are limited therapeutic options for patients with advanced midgut NETs progressing on first-line somatostatin analog therapy.
Aim(s): Evaluate the activity and safety of 177Lu-DOTA0-Tyr3-Octreotate (Lutathera®) in patients with advanced, progressive sstr positive midgut NETs.
Materials and methods: 230 patients grade 1-2 metastatic midgut NETs were randomized to Lutathera 7.4 GBq every 8 weeks (x4 administrations) vs Octreotide LAR 60 mg every 4 weeks. Primary endpoint was PFS (RECIST 1.1) with tumor assessment every 12 weeks. Secondary objectives included ORR, OS, toxicity and QoL.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Jonathan Strosberg
Keywords: Lutathera, PRRT, NET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1676 NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors
Introduction: Impairment in quality of life caused by tumor load and hormone-related symptoms is frequent in GEP-NET patients. In the Phase III NETTER-1 trial, patients with advanced, progressive midgut NETs were randomized to treatment with 177Lu-DOTATATE (177Lu; Lutathera®) or high-dose (60 mg) Octreotide LAR (Oct).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Prof. Jonathan Strosberg
#2985 Peptide Receptor Radionuclide Therapy (PRRT) Outcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll?
Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Virginia Liberini
#2038 Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate vs. High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors
Introduction: The NETTER-1 final per-protocol statistical analysis (cut–off date 24.07.2015) of PFS, the primary endpoint of the study, showed a significant difference (p
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Jonathan Strosberg
Authors: Strosberg J, Wolin E, Chasen B, Kulke M, ...
#2849 PRRT Neuroendocrine Tumor Response Assessment Using Circulating Transcript Analysis: The NETest
Introduction: The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
#2894 Single Institution Experience with Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
Introduction: Neuroendocrine tumors (NETs) are a rare and heterogenous group of tumors with rising incidence. Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogue is an encouraging systemic treatment modality with minimum side effects.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Heying Duan
Authors: Duan H, Ninatti G, Girod B, Ferri V, ...
Keywords: NET, PRRT, ORR, PFS